Details for Menveo vaccine and its components.
Registered for use in people aged ≥2 months.
MenACWY-CRM — quadrivalent meningococcal (serogroups A, C, W-135, Y)–CRM197 conjugate vaccine
Lyophilised powder containing serogroup A in a monodose vial with a pre-filled syringe or vial containing serogroups C, W-135 and Y in saline suspension.
Each 0.5 mL reconstituted dose contains:
- 10 µg meningococcal polysaccharide serogroup A conjugated to 16.7–33.3 µg Corynebacterium diphtheriae CRM197 protein
- 5 µg meningococcal polysaccharide serogroup C conjugated to 7.1–12.5 µg C. diphtheriae CRM197 protein
- 5 µg meningococcal polysaccharide serogroup W-135 conjugated to 3.3–8.3 µg C. diphtheriae CRM197 protein
- 5 µg meningococcal polysaccharide serogroup Y conjugated to 5.6–10 µg C. diphtheriae CRM197 protein
Also contains traces of:
- natural rubber
Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/vaccines/menveo.